Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region

Joanne Lagmay, MD

Pediatric Hematologist/Oncologist (Child Cancer Specialist)

Photo of Joanne Lagmay

About me

Joanne Lagmay, M.D., is board-certified in general pediatrics and pediatric hematology/oncology. Her main focus has been the multidisciplinary treatment of pediatric solid tumors, specifically pediatric sarcoma of the bone and soft tissue. She also has special interest in pediatric palliative care. Dr. Lagmay participates in several national professional societies and committees, including the Children’s Oncology Group, American Society of Pediatric Hematology and Oncology, American Society of Hematology, Connective Tissue Oncologic Society, and STOP Children’s Cancer. Her practice integrates translational research in targeted radionuclide therapies for osteosarcoma in collaboration with UF Veterinary Medicine, Biomedical Engineering, Chemistry, Material Science Engineering and Radiation Oncology. Her direct collaboration with pediatric oncology colleagues in Florida has resulting phase I clinical trials for pediatric cancer patients in the state. Dr. Lagmay came to UF in 2009 from Nationwide Children’s Hospital, The Ohio State University where she was a fellow in pediatric hematology/oncology. She did her pediatric residency training at the Children’s Hospital of Monmouth in New Jersey, where she also served as chief resident.

My locations

Active clinical trials

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles…

Investigator
Joanne Lagmay
Status
Accepting Candidates
Ages
12 Months - 21 Years
Sexes
All
Neuroblastoma Maintenance Therapy Trial (NMTT)

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ±…

Investigator
Joanne Lagmay
Status
Accepting Candidates
Ages
1 Year - 30 Years
Sexes
All

My research

Top areas of exploration

  • Neoplasm Recurrence, Local , 4 publications
  • Combined Modality Therapy , 3 publications
  • Biomarkers, Tumor , 3 publications
  • Antineoplastic Combined Chemotherapy Protocols , 3 publications

Research activity

23 publications

376 citations

Why is this important?
View more of Joanne Lagmay's research activity

Search our accepted insurances list

Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.

See all

My areas of focus